NCT07014735View on ClinicalTrials.gov

Effect of Hyperglycaemia and Moxifloxacin on QTc Interval in T2DM

NARecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 13, 2023

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2025

Conditions
Diabetes Type 2Hyperglycaemia (Diabetic)QT Interval, Variation inTorsades de Pointes
Interventions
DRUG

glucose

Participants will receive treatments with glucose or matching placebo (please see study design section).

DRUG

moxifloxacin

Participants will receive moxifloxacin or matching placebo (please see study design section).

Trial Locations (1)

SE1 1YR

RECRUITING

Richmond Pharmacology Ltd., London

All Listed Sponsors
collaborator

Richmond Research Institute

INDUSTRY

lead

Richmond Pharmacology Limited

INDUSTRY